Top News Stories For November 13 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories For November 13 2017”

Verastem Inc Price Target Raised By Cantor Fitzgerald

Verastem Inc price target was raised to $17 by Cantor Fitzgerald last week. The new $17 price target represents 330% upside from the previous close of $3.95. Cantor has a Buy rating on the stock.

Cantor Fitzgerald is respected on Wall Street but they do not have the most accurate analysts IMO. Oppenheimer Holdings Inc is a more followed analyst than Cantor Fitzgerald. It's no surprise then that I think it's more significant that on October 12, 2017, Oppenheimer reiterated their Buy rating on Verastem Inc stock and set a price target of $6 which represents an upside of 52% from the previous close. The $6 price target seems more down-to-earth and achievable than Cantor's stratospheric $17 price target.

Global Blood Therapeutics Rising Large Players Volume

Global Blood Therapeutics stock has excellent large players volume action. Large players volume is in an uptrend and is confirmed by the rising Twiggs Money Flow.

Global Blood Therapeutics stock has 11 Buy ratings from analysts. Price targets average to $55.73 which represents 71.73% upside from the previous closing price. Needham & Company, one of the most followed analyst firms because of their excellent record, set a price target on the stock today of $51 which is 57% upside from the previous close at $32.45.

Flexion Therapeutics Stock Higher on FDA Approval of Zilretta

Flexion Therapeutics stock has rocketed higher on FDA approval of Zilretta. Zilretta is the first and only extended-release, intra-articular injection for osteoarthritis knee pain.

Michael Clayman, M.D., President and Chief Executive Officer of Flexion said, "The approval of Zilretta marks a major advancement in the treatment landscape for managing OA knee pain. It comes at a time when our society is in urgent need of non-addictive therapies to help the millions of Americans who suffer from this condition. We believe that Zilretta has the potential to be a transformative medicine for the more than five million patients who receive an intra-articular injection for OA knee pain each year."

Zilretta's peak potential sales could hit $750 million but that could be a conservative estimate. With additional revenues from label expansion and potential new indications such as osteoarthritis of the hip and shoulder (for which clinical trials are anticipated to initiate by the end of this year), Zilretta's sales could easily top $1 billion and that doesn't include international sales.

Cryoport Stock Gets Janney Montgomery Scott Price Target of $12

Cryoport stock received a price target hike from Janney Montgomery Scott to $12 which is 42% upside from the previous close of $8.45.

Cryoport provides cryogenic logistics solutions to the life sciences industry through its packaging, information technology, and cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

If someone wants to ship something cryogenically using UPS, FedEx, or DHL, they are directed to Cryoport by these shipping companies.

A whopping 70% of Cryoport's business comes from biopharma companies. About 15% comes from human reproduction needs and another 15% comes from animal health needs.

Celsion Corporation Retraces 61.8 Percent After Exploding Higher

Celsion Corporation has done a 61.8 percent Fibonacci retracement after exploding 180 percent higher last week after releasing data from its Ovation Study.

The Ovation Study is a Phase Ib dose escalating clinical trial combining GEN-1, the company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced Stage III/IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.

Sofi AI Market Sentiment Gauge

Sofi AI Market Sentiment Gauge

Market is neither overbought or oversold.